Abstract

Teixobactin, is first new type of antibiotic in 30 years with properties that minimise development of bacterial
resistance. It is discovered by scientist from Northeastern University and Novobiotic Pharmaceuticals by
isolating it with the help of iChip technology. Unlike other antibiotics which act on protein targets and
develop resistance, it acts on unique target in cell wall synthesis and so there is lack of resistance. It is
active against MRSA, M. tb and many other superbugs. It is undergoing preclinical studies and clinical
trials will take several years before the drug reaches the pharmacy shelves.